| Similar Articles |
|---|
 |
Bio-IT World
April 15, 2003
Michael Greeley |
Bio Battles Upstream As biotech business models evolve, the question remains: Which will survive?   |
Bio-IT World
July 15, 2003
Michael Greeley |
Finally, the Bottom Has pharma bought all the solutions it needs? The flood of genomic data indicates no. |
Bio-IT World
September 11, 2003 |
Show Me the Evidence ... Some emerging bio-IT services companies are beginning to attract venture capital. |
Bio-IT World
July 2005
Michael A. Greeley |
CEO Lessons on Product and Market In the face of extraordinary R&D budgets generated by biopharma industries, bio-IT companies must refine their value propositions in the hopes that meaningful (predictable and repeatable) revenue streams can be created. |
Bio-IT World
March 8, 2005
Michael A. Greeley |
What's New at Big Blue? The scale of computing has improved dramatically in the life sciences. But has the bio-IT industry over-promised, and does it risk under-delivering? Ultimately, customers will want to see a return on these investments, and that won't happen in two to three years. |
Bio-IT World
October 10, 2003 |
Funds Up Venture financing numbers are in for Q2, and the news is not all bad. |
Bio-IT World
Dec 2005/Jan 2006
Michael A. Greeley |
Infinite Demand for the Unavailable The bio-IT field is once again attracting venture capital, but at a more moderate, deliberate pace than the euphoria of the late 1990s. |
Bio-IT World
May 9, 2003
Michael Greeley |
Mechanistic Models Investors are backing predictive modeling software that could speed drug development. |
Bio-IT World
October 14, 2004
Michael Greeley |
Go East Business is great in China, and the government is strongly encouraging the local biotech industry. |
Bio-IT World
January 13, 2003
Michael Greeley |
What Do We Do Now? Like it or not, the supply of capital is an important ingredient in the continued development of the bio-IT industry. Appreciating and understanding the forces currently at work in the VC marketplace can only help in raising capital. |
Bio-IT World
March 10, 2003
Michael Greeley |
Too Much Informatics Did bioinformatics companies forget about the fundamental law of supply and demand? |
Bio-IT World
August 13, 2003
Michael Greeley |
Two Cents on the '$1,000 Genome' Are venture capitalists still looking for 'the killer app'? Funding the next big idea won't be so easy. Affordable, individualized genome sequencing holds great promise, but making the claims sound too grandiose can be dangerous. |
Bio-IT World
December 15, 2003
Michael Greeley |
Tiny Devices, Big Opportunities Parallel advances in drug formulation and microprocessing and other manufacturing technologies are creating new products and services as these industries start to intersect. |
Bio-IT World
April 2006
Michael A. Greeley |
The Good, The Bad, and The Ugly VCs will not support a sector where consistent compelling exits are not evident. Unfortunately, the bio-IT field still suffers from this. |
Bio-IT World
February 2006
John Russell |
Marvelous Models of Biological Systems Here are highlights from a roundtable discussion with researchers representing academia and pharmaceuticals, as well as executives from modeling technology providers on whether or not Pharma is ready to bet on computational modeling of biological systems. |
Bio-IT World
July 11, 2002
Kevin Davies |
Counting the Cost of Drug Discovery Much of the trouble ensnaring the drug industry is blamed on the exorbitant cost of drug discovery. Tangible proof that the bio-IT revolution will economize drug discovery is emerging, but there is still a long way to go. |
Bio-IT World
September 2005
Michael A. Greeley |
Harvesting Patient Data Longitudinal data tools will allow pharmaceuticals to optimize sales force deployments and distribution strategies based on medical impacts of their compounds across various population sets. |
Bio-IT World
March 10, 2003 |
Champions of the Bio-IT World PART II Senior executives from bioinformatics and biotech companies talk about the goals, philosophies, and products that each organization brings to the bio-IT table. |
Bio-IT World
January 12, 2004
Michael A. Greeley |
What You See Is What You Get Better image analysis, better business models. The transition from analog to digital will allow systems biology to reach its full potential. |
Bio-IT World
October 9, 2002
Debra Goldfarb |
A Study in Contrasts Recently, IDC conducted a pair of focus groups as part of a broader study on technology adoption across bio-IT workloads. |
Bio-IT World
May 19, 2004
John Russell |
Informatics Black Boxes ... Not! Vertex's chief technical officer, discusses informatics' bad reputation, buying vs. building, open-source tools, and ROI on IT. |
Bio-IT World
September 9, 2002 |
Letters Frustrated in Gene Town... IT for the Biologists, by the Biologists?... |
Bio-IT World
July 11, 2002
Mike Fitzgerald |
Funding the Future Investor G. Steven Burrill, CEO of Burrill & Company, helps biotech companies fulfill their potential. He talked recently about his view of the bio-IT field. |
Bio-IT World
November 2006
Alan S. Louie |
Signs of Life in Life Sciences IT Spending Pharmaceutical and other life science companies are confronting explosive growth in the volume of data being generated from R&D programs including high-throughput discovery instrumentation, molecular imaging (pre-clinical and clinical), and access to external data sources. |
Bio-IT World
January 13, 2003
Malorye Branca |
Charting a Course After the Genome A quarterly feature looks at the financial numbers in the bio-IT industry. |
